Search clinical trials for: Xisomab 3G3

Total 366 results

Aronora, Inc.

Completed

Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects

Thrombosis

United States
Aronora, Inc.

Completed

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
OHSU Knight Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...

Terminated

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Malignant Solid Neoplasm | Lymphoma | Plasma Cell Myeloma

United States
Eli Lilly and Company

Terminated

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor (GIST)

United States, Belgium, Germany, Netherlands, Poland, Spain
Eli Lilly and Company

Completed

Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available

Solid Tumors

United States
Abbott

Completed

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

HCV Infection

United States
Taiho Pharmaceutical Co., Ltd.

Completed

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Healthy Male Subjects

Japan
Eli Lilly and Company

Completed

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Metastasis | Malignancy

Japan
AbbVie

Not yet recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
TeneoOne Inc.

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, United States, Canada, Spain, France, Denmark, United Kingdom
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393

Type II Diabetes Mellitus

Korea, Republic of
Sichuan Clover Biopharmaceuticals, Inc.

Completed

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

Malignant Pleural Effusion

China
Quigley Pharma, Inc.

Completed

Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

Diabetic Neuropathy

United States
Chong Kun Dang Pharmaceutical

Unknown

Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults

Hypertension | Dyslipidemias

Korea, Republic of
Arvinas Inc.

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

United States, Spain
AbbVie

Active, not recruiting

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Relapsed/Refractory Multiple Myeloma

Japan
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Alzheimer's Disease

United States
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate the PK and Safety of CKD-393

Type II Diabetes

Korea, Republic of
Wohlstand Pharmaceutical
Concentra Educación e Investigación Biomédica

Not yet recruiting

Beta-glucans for Hospitalised Patients With COVID-19

COVID-19

Chile
Otonomy, Inc.

Completed

OTO-313 in Subjects With Unilateral Subjective Tinnitus

Subjective Tinnitus

United States, United Kingdom, Germany, Poland
Otonomy, Inc.

Completed

OTO-313 in Subjects With Subjective Tinnitus

Tinnitus, Subjective

United States
pH Pharma

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy Subjects

Healthy Volunteer

United States
AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Abbott

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

HCV Infection

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals

Terminated

Study Evaluating Multiple Ascending Dose in Schizophrenia Patients

Healthy
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
AbbVie

Not yet recruiting

A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe

Healthy Volunteers
Vaxxinity, Inc.

Recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants

Migraine

Belgium
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-323 in Healthy Subjects

RSV Infection

United States
Alpine Immune Sciences, Inc.

Completed

A Study of ALPN-303 in Adult Healthy Volunteers (RUBY-1)

Healthy Volunteers

Australia
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals

Terminated

Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients

Healthy
pH Pharma

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Otherwise Healthy Overweight or Obese

United States
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Becton, Dickinson and Company

Completed

Evaluation of Blood Volume and Perceived Pain During Fingerstick Monitoring of Blood Glucose

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Phoenicis Therapeutics

Terminated

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

Epidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, Dominant

United States, Spain, France
Amgen

Terminated

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Migraine

United States
Amgen

Completed

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Migraine

United States
Wenzhou Medical University

Recruiting

Comparison of Outcomes With Multifocal Intraocular Lenses (COMIL)

Cataract

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Eli Lilly and Company

Completed

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Glioblastoma Multiforme

United States
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety Profile of CKD-333

Hypertension | Dyslipidemias

Korea, Republic of
Kowa Company, Ltd.

Completed

Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

Hepatic Neoplasm Malignant Recurrent

Japan
AbbVie

Recruiting

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Solid Tumors

United States, Israel, Japan
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
AbbVie

Withdrawn

An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)

Sjogren's Syndrome (SS)

Netherlands
Achaogen, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789

Healthy Volunteers

Australia
PD Dr. med. Eckart Bertelmann

Completed

Visual Acuity After the Combined Binocular Implantation of +2.0 Diopters and +3.0 Diopters Oculentis Multifocal Intraocular Lenses.

Cataract

Germany
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150

Type 2 Diabetes

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

Type2 Diabetes Mellitus

Korea, Republic of

3

Subscribe